Acne, Hyperpigmentation, Post-inflammatory Hyperpigmentation
Conditions
Brief summary
The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.
Detailed description
Hyperpigmentation is characterized as an increase in pigment on the skin and is a common skin condition in individuals with skin types III to VI on the Fitzpatrick skin classification scale. Hyperpigmentation can be localized to an area in the form of post-inflammatory hyperpigmentation or diffused in the form of melasma. One of the treatments that are used to treat hyperpigmentation is tranexamic acid (TXA) which is a third-generation bioactive and is formally known to work as a plasmin inhibitor. Since TXA is hydrophilic in nature and has a strong hydrogen-bonding capacity, it has an insufficient skin permeability. Similar to TXA esters, Cetyl Tranexamate Mesylate (CTM) is hypothesized to have greater permeability and this study will evaluate the effects of CTM on the appearance of post-inflammatory hyperpigmentation.
Interventions
OTHERTopical Cetyl Tranexamate Mesylate
Topical product will be applied onto clean skin morning and night.
Sponsors
Actera
Integrative Skin Science and Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and females between the ages of 14 years of age until 55 years of age * Individuals experiencing 3 different areas minimum of facial post-inflammatory hyperpigmentation in those with acne
Exclusion criteria
* Individuals who are pregnant or breastfeeding. * Prisoners. * Adults unable to consent. * Those who are unwilling to discontinue hydroquinone, vitamin A/C/E, azelaic acid, kojic acid, bakuchiol, licorice root, retinol, niacinamide, alpha arbutin, and oral or topical tranexamic acid for two weeks to meet the washout criteria prior to enrolling and for the duration of the study. * Subjects with any of the following facial cosmetic treatments within the past 3 months or those who are unwilling to withhold the following facial cosmetic treatments during study including microdermabrasion, intense pulsed light (IPL), peels, laser treatments, acid treatments, or any other medical treatment administered by a physician or skin care professional which is designed to improve skin pigmentation. * Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study. * Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Facial skin pigment intensity of 3 pre-identified lesions | 2 weeks | Change in the appearance of pigment intensity (melanin measurement) of 3 pre-identified hyperpigmented lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Facial skin pigment intensity of 3 pre-identified lesions | 1 week | Change in the appearance of pigment intensity (melanin measurement) of 3 pre-identified hyperpigmented lesions |
| Self-perception of skin pigmentation | 1 week | Survey-based self-assessment of facial skin pigmentation |
| Self-perception of skin redness | 1 week | Survey-based self-assessment of aspects of skin redness |
Countries
United States
Outcome results
None listed